UY39681A - Derivados de ciclobutilo 1,3–sustituidos y sus usos - Google Patents

Derivados de ciclobutilo 1,3–sustituidos y sus usos

Info

Publication number
UY39681A
UY39681A UY0001039681A UY39681A UY39681A UY 39681 A UY39681 A UY 39681A UY 0001039681 A UY0001039681 A UY 0001039681A UY 39681 A UY39681 A UY 39681A UY 39681 A UY39681 A UY 39681A
Authority
UY
Uruguay
Prior art keywords
substituted cyclobutyl
treatment
disorders
diseases
derivatives
Prior art date
Application number
UY0001039681A
Other languages
English (en)
Spanish (es)
Inventor
Donglei Liu
James J Powers
Julien Papillon
Stefan Peukert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY39681A publication Critical patent/UY39681A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/74Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001039681A 2021-03-26 2022-03-22 Derivados de ciclobutilo 1,3–sustituidos y sus usos UY39681A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163166289P 2021-03-26 2021-03-26

Publications (1)

Publication Number Publication Date
UY39681A true UY39681A (es) 2022-10-31

Family

ID=80999265

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039681A UY39681A (es) 2021-03-26 2022-03-22 Derivados de ciclobutilo 1,3–sustituidos y sus usos

Country Status (14)

Country Link
US (2) US11845730B2 (https=)
EP (1) EP4313951A1 (https=)
JP (1) JP2024510778A (https=)
KR (1) KR20230162660A (https=)
CN (1) CN117062804A (https=)
AR (1) AR125196A1 (https=)
AU (1) AU2022244467A1 (https=)
CA (1) CA3214066A1 (https=)
IL (1) IL307189A (https=)
MX (1) MX2023011377A (https=)
PY (1) PY2221203A (https=)
TW (1) TW202304864A (https=)
UY (1) UY39681A (https=)
WO (1) WO2022201097A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR125196A1 (es) * 2021-03-26 2023-06-21 Novartis Ag Derivados de ciclobutilo 1,3-sustituidos y sus usos
WO2024062389A1 (en) * 2022-09-21 2024-03-28 Bausch + Lomb Ireland Limited Crystalline polymorph forms of a trpv1 antagonist and formulations thereof
US20240148709A1 (en) * 2022-11-08 2024-05-09 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7514562B2 (en) * 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
RU2451014C2 (ru) 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
EP2050734A1 (en) 2006-07-13 2009-04-22 Kyowa Hakko Kirin Co., Ltd. Pentadienamide derivative
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
WO2012072512A1 (en) * 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
DE102010052781A1 (de) 2010-11-30 2012-05-31 Trw Automotive Gmbh Befestigungsvorrichtung und Befestigungsbaugruppe zur Befestigung eines Gasgenerators und Fahrzeuginsassenrückhaltesystem
TW201302681A (zh) * 2011-03-25 2013-01-16 Abbott Lab Trpv1拮抗劑
JP2014510768A (ja) * 2011-04-11 2014-05-01 グラクソ グループ リミテッド Trpv1アンタゴニストとしてのn−シクロブチルイミダゾピリジンメチルアミン
US9747862B2 (en) 2015-11-02 2017-08-29 Castar, Inc. Method of immersive rendering for wide field of view
US10269906B2 (en) * 2016-11-30 2019-04-23 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device having two spacers
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
AU2019392904B9 (en) 2018-12-07 2022-12-22 University Of Maryland, Baltimore Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors
AR125196A1 (es) * 2021-03-26 2023-06-21 Novartis Ag Derivados de ciclobutilo 1,3-sustituidos y sus usos

Also Published As

Publication number Publication date
IL307189A (en) 2023-11-01
AU2022244467A1 (en) 2023-10-12
JP2024510778A (ja) 2024-03-11
EP4313951A1 (en) 2024-02-07
AR125196A1 (es) 2023-06-21
PY2221203A (es) 2022-11-24
US12435040B2 (en) 2025-10-07
MX2023011377A (es) 2023-10-06
US11845730B2 (en) 2023-12-19
WO2022201097A1 (en) 2022-09-29
CN117062804A (zh) 2023-11-14
BR112023019496A2 (pt) 2023-12-05
US20220324811A1 (en) 2022-10-13
US20240308965A1 (en) 2024-09-19
TW202304864A (zh) 2023-02-01
CA3214066A1 (en) 2022-09-29
KR20230162660A (ko) 2023-11-28

Similar Documents

Publication Publication Date Title
CL2025002925A1 (es) Compuestos derivados de pirido[4,3–d]pirimidina y uso para tratar cáncer.
CR20230256A (es) Compuestos farmacéuticos
UY39681A (es) Derivados de ciclobutilo 1,3–sustituidos y sus usos
ECSP21004787A (es) Inhibidores de inflamasoma nlrp3
MA59373B1 (fr) [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2
AR128931A1 (es) Inhibidores del factor b del complemento y usos de los mismos
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
GT200400116A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
DOP2010000064A (es) 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
AR123685A1 (es) Antagonistas del mrgx2
EP4663190A3 (en) Muscarinic receptor agonists
CR20210630A (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
AR127470A1 (es) Inhibidores de lrrk2
AR133953A1 (es) Inhibidores del factor b del complemento y usos de los mismos
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
CL2021000282A1 (es) Inhibidores de ckd8/19
ECSP19084722A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
ZA202306305B (en) Pharmaceutical compounds
AR132880A1 (es) Derivados de heteroaril como inhibidores de ddr
AR134411A1 (es) Compuestos de uracilo
AR134062A1 (es) Inhibidores de ras y sus métodos de uso
GEAP202516807A (en) Dopamine d3/d2 receptor modulating compounds